MirZyme Therapeutics offers the end-to-end preeclampsia solution. It is an early-stage clinical women's health biopharmaceutical company that has uncovered what causes preeclampsia and how to predict and prevent it. We have a pipeline of tailored therapeutics to prevent preeclampsia and Small for Gestational Age babies.
Our digital diagnostic algorithm takes blood test results and tells a pregnant woman half way through pregnancy if she is going to develop preeclampsia.
MirZyme has a highly skilled, diverse, and deeply dedicated team. The core team have worked together for over a decade.
$40M non-dilutive competitive grants awarded leading to breakthrough innovation
Global patents granted in 30 countries
Novel diagnostic algorithm proven in human clinical trials
Fast-track Innovation Passport awarded by Medicines & Healthcare products Regulatory Agency for development of MirZyme's primary medicine
Recognized by Department for Science, Innovation & Technology as a UK leading FemTech in Biotechology
MirZyme has successfully completed preclinical efficacy studies in widely used disease models and has conducted effective, prospective clinical diagnostic studies in humans using the company’s proprietary know-how and intellectual property.